


[図1]


γδTCR
CD3
αβTCR


[図2]


61.2%
24.5%
7.69%
Comp-APC-A: Vdelta2
Comp-FITC-A: Vdelta1
Vdelta2
Vdelta1


[図3]


120
100
80
60
40
20
0
-20
% Cytotoxicity
iPSC-γδT
16:1
8:1
4:1
2:1
1:1
0.5:1
Effector : Target ratio


[図4]


Fold change from Day0
100
10
1
0
5
10
15
days after stimulation


[図5]


γδTCR
CD3
CD3
100
Vγ9
Vδ2
δ2γ9
99.9


[図6]


γδTCR
CD3
Q1
0
Q2
99.8
Q4
0.024
Q3
0.17
Vγ9
CD3
Q9
0.012
Q10
99.9
Q12
0.048
Q11
0.036


[図7]


Cell counts
5×10⁸
5×10⁷
5×10⁶
0
5
10
Days after stimulation


[図8]


Cell counts
5×10⁷
5×10⁶
0
5
10
Days after stimulation


[図9]


% killing for 2 hrs
100
50
0
CD19⁺ Raji target
CD19⁻ CCRF-CEM
16
8
4
2
1
0.5
Effector/target ratio

[図10]


% killing for 2 hrs
100
50
0
CD19⁺ Raji target
CD19⁻ CCRF-CEM
16
8
4
2
1
0.5
Effector/target ratio

[図11]


100
50
0
Percent survival
0
10
20
30
40
days after inoculation
Control
CD19-CAR igdT

[図12]

